Landmark data from the phase 3 SOLO-1 (NCT01844986) and SOLO-2 (NCT01874353) trials collectively established olaparib (Lynparza) as a central component of maintenance therapy for patients with BRCA-mutated ovarian cancer, according to Kevin Elias, MD.1,2
“Olaparib is still very much one of the treatments of choice for women with somatic or germline [BRCA] mutations who have just finished primary therapy. We have the longest safety and efficacy data for olaparib compared with other PARP inhibitors, and we know that for this subgroup of patients, the benefit is tremendous,” Elias said during an interview with OncLive®. Elias is a gynecologic oncologist and the Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research at the Cleveland Clinic in Ohio.
In the interview, Elias discussed the need for germline and somatic testing at diagnosis, the ongoing investigation of optimal treatment duration, and safety considerations associated with the use of PARP inhibitors.
Elias: The SOLO-1 and SOLO-2 trials were looking at maintenance olaparib therapy. The SOLO studies focused on individuals with germline mutations in the BRCA1 or BRCA2 genes, but in SOLO-1, patients could have somatic mutations in BRCA1 or BRCA2. SOLO-1 was looking at newly diagnosed women who had just finished primary therapy with surgery and a platinum doublet for ovarian cancer and randomized them to either maintenance olaparib therapy, which was [given at a dose of] 300 mg twice daily, or placebo for up to 2 years.
The primary outcome was progression-free survival [PFS], and for women randomized to olaparib, the chances of progression or death were reduced by 70% [compared with placebo]. It was a very positive study.
SOLO-2 was a little bit different [because it looked] at women with recurrent ovarian cancer and only focused on germline mutation carriers. All patients in SOLO-2 had received at least 2 lines of platinum-based chemotherapy and were platinum sensitive in the most recent line. These patients were also randomized to 300 mg of olaparib twice daily or placebo.
Similarly, there was also a strong PFS benefit in that setting, although the magnitude of benefit in the recurrent setting was not quite as great as in the primary setting. In SOLO-2, the median PFS in the olaparib group was 19.1 months vs 5.5 months in the placebo group.
The long-term survival data from SOLO-1 showed that, at 7 years from randomization, the risk of death [was reduced by 45%] for those receiving olaparib vs those in the placebo group. Almost half [45.3%] of patients in the olaparib group were still alive and had not recurred at 7 years, whereas [79.4%] of patients in the placebo group had recurred or died [within that period].
[These data] highlight the importance of understanding underlying germline predisposition in ovarian cancer at initial diagnosis. The earlier we know if someone is a BRCA1 or BRCA2 mutation carrier, either at a germline or somatic level, the sooner we’re able to get them appropriately onto olaparib therapy. We can make a strong recommendation that it alters the treatment trajectory.
What I counsel my patients is that, looking across the studies with olaparib, if they’re a good candidate based on the study criteria, we can cut their risk of relapse or death by more than half by going on [PARP inhibitor] maintenance therapy.
We still have questions about olaparib as far as the duration of therapy. In the initial studies, all patients were randomized to 2 years of olaparib therapy. There’s currently a study funded by the NRG that’s randomizing patients to either 2 years or 1 year of maintenance therapy. Two years of therapy was chosen rather empirically, and it could be that patients might benefit from shorter courses, which would be beneficial not only in terms of cost but also [adverse] effects [AEs].
We know these medicines have a risk of myelodysplastic syndrome, and perhaps by exposing patients to shorter durations of therapy, we might reduce one of the most concerning AEs of these drugs.
Academy Award®-nominated director Paul Greengrass’s film for Focus Features, The Uprising, has added to its cast with the addition of Jamie Bell (Half-Man, All Of Us Strangers, Rosebush Pruning), Cosmo Jarvis (Warfare, Shogun), Thomasin…
Oscar-winning actress Diane Keaton passed away on Saturday, October 11, 2025. Following her death this past weekend, co-stars, colleagues, friends, and movie lovers shared their feelings about the…
Dearest gentle reader, Lady Whistledown — voiced by Julie Andrews — is back.
Netflix released a trailer for the fourth season of “Bridgerton” on Monday, and the Ton’s resident gossip columnist promised to have all the delightful…
Earth’s Ediacaran Period, roughly 630 to 540 million years ago, has always been something of a magnetic minefield for scientists.
During earlier and later time periods, tectonic plates kept a steady pace, climate zones were normal, and the…
Bombardier is proud to announce that Comlux, a leading business aviation company, will take delivery of the industry-defining Global 8000(1) aircraft in 2026. Renowned for its expertise in long-range operations with aircraft such as the Bombardier Global 6000 and Global 6500, Comlux is strategically enhancing its charter offering with Bombardier’s flagship jet. With its industry-leading ultra-long-range capabilities and top speed, the Bombardier Global 8000 aircraft is the ideal complement to Comlux Aviation’s fleet—delivering exceptional performance, comfort, and efficiency for premium global travel.
“The Bombardier Global 8000 aircraft integrates perfectly into our long-range fleet, in between our wide-body fleet and our Global 6500 fleet,” said Comlux Aviation CEO, Andrea Zanetto. He continues: “At Comlux, we offer comfort in ownership and luxury in flight! We have built our reputation on delivering premium global travel solutions and this aircraft allows us to offer ultra-long-range. Comlux continuously elevates its fleet to offer clients an unmatched charter experience across the globe with a diversified fleet. The delivery of the Global 8000 will mark the beginning of an exciting new chapter, as we continue to attract more clients to manage the operation of Global 7500 and Global 8000.”
“The Bombardier Global 8000 jet offers the perfect balance of ultra-long-range performance and refined passenger experience—an ideal fit for Comlux’s discerning clientele,” said Éric Martel, President and CEO, Bombardier. “As our valued business relationship continues to grow, the Global 8000 aircraft will deliver its exceptional performance and signature smooth ride to Comlux’s customers around the world.”
The Global 8000(1), the world’s fastest purpose-built business jet, represents a new era of performance, comfort and innovation. With its unmatched speed and a range of 8,000 nautical miles, the aircraft is designed to meet the needs of the most discerning travelers—delivering seamless connectivity between global cities with exceptional onboard luxury.
Comlux’s upcoming delivery marks a significant milestone in the continued adoption of the Bombardier Global 8000 jet by leading operators worldwide. The aircraft’s advanced technology and refined cabin experience make it a standout choice for those seeking the ultimate in private aviation.
At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.
For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.
Bombardier customers operate a fleet of more than 5,100 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries.
Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.
Comlux Group is one of the leaders in business aviation industry. For over 20 years, the company has been engineering luxury for VIP customers seeking personal and professional management of their private aviation needs, including aircraft sales and acquisitions, aircraft operations and charter management. Headquartered in Switzerland with a global presence around the world, Comlux delivers world-class, Swiss-made business aviation services.
For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit
bombardier.com.
Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.
General media contact webform
Bombardier, Global, Global 6000, Global 6500, Global 7500 and Global 8000 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.
(1)The Global 8000 aircraft is currently under development and remains to be finalized and certified. It is expected to enter into service in 2025. See forward-looking statements disclaimer hereafter. All specifications and data are approximate and may change without notice and are subject to certain operating rules, assumptions and conditions.
Forward-looking statements
This press release contains certain forward-looking statements. By their nature, forward-looking statements require the Corporation to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from those set forth in the forward-looking statements. Please refer to the “Forward-Looking Statements” disclaimer contained in Bombardier Inc.’s most recently published financial report for additional details.
Google rolled out AI trending previews in Discover and will add a “What’s new” sports feed to U.S. mobile search in coming weeks.
Ina Garten is cooking up something funny for the latest season of her Food Network show. The Barefoot Contessa will welcome comedian Tina Fey for the premiere episode of Be My Guest, which kicks off on October 19. In the series, now in its…